Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase III trial of arbaclofen placarbil for the treatment of spasticity in patients with multiple sclerosis. A 13-week double-blind, randomised, placebo-controlled trial followed by an open-label extension.

Next Previous
Trial Profile

Pivotal phase III trial of arbaclofen placarbil for the treatment of spasticity in patients with multiple sclerosis. A 13-week double-blind, randomised, placebo-controlled trial followed by an open-label extension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arbaclofen placarbil (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Sponsors XenoPort

Most Recent Events

  • 20 May 2013 Status changed from active, no longer recruiting to completed, as reported by a Xenoport media release.
  • 20 May 2013 Co-primary endpoints 'Statistically significant improvements in scores on the Ashworth Scale and the 7-point Patient Global Impression of Change scale' have not been met, as reported by a XenoPort media release.
  • 23 Mar 2013 182 patients (91% of the targeted enrollment) have been enrolled to date.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top